Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
Capricor Therapeutics (NASDAQ: CAPR) said the FDA Cellular, Tissue and Gene Therapies Advisory Committee voted 3-9 (0 abstain) that available evidence does not support Deramiocel’s effectiveness for cardiomyopathy in Duchenne muscular dystrophy. The vote is non-binding and focused on a narrower indication than Capricor proposed. Capricor targets an Aug. 22, 2026 PDUFA action date.
How this was made
The 30-second read
Why it matters
The FDA advisory committee concluded available evidence does not support effectiveness for Deramiocel in DMD cardiomyopathy, which can weigh on approval expectations despite being non-binding. Capricor reiterates confidence in HOPE-3 data and targets FDA action on Aug 22, 2026.
Market read
This is a direct regulatory sentiment shock for CAPR tied to the upcoming PDUFA decision timeline, with a negative advisory vote for effectiveness in the cardiomyopathy indication.
What to watch
The article says the committee’s feedback was directionally supportive on upper limb function and primary endpoint PUL 2.0, which could support an FDA decision that differs from the advisory vote.
Background
Capricor’s Deramiocel (CAP-1002) is an allogeneic cardiosphere-derived cell therapy in late-stage development for Duchenne muscular dystrophy, with FDA advisory committee review focused on a narrower cardiomyopathy indication.
Ticker impact
FDA advisory committee voted 3-9 that available evidence does not support Deramiocel effectiveness for DMD cardiomyopathy, non-binding.
Likely downside pressure or elevated volatility in CAPR into the PDUFA date, with potential for sharp reversals if FDA signals a path forward despite the vote.
The committee’s vote directly challenges effectiveness for the narrower indication, even though it is non-binding and the article notes supportive discussion on upper limb function and confidence in HOPE-3 data.
Market effects
Highlights heightened scrutiny for cell/exosome therapies in rare-disease cardiomyopathy indications, potentially affecting sentiment across similar late-stage programs.
US biotech sentiment may soften for rare-disease regenerative medicine names around FDA advisory outcomes.
EMA designations and regulatory pathways remain relevant, but the US advisory vote can still influence global investor risk appetite for comparable assets.
Counterpoint
Because the vote is non-binding and the question was narrower than Capricor’s proposed indication, investors may be over-discounting the probability of eventual approval for the broader benefit-risk profile.
Key entities
- companyCapricor Therapeutics
NASDAQ-listed biotech developing Deramiocel for Duchenne muscular dystrophy; subject of the FDA advisory committee update.
- product_candidateDeramiocel (CAP-1002)
Allogeneic cardiosphere-derived cell therapy reviewed by the FDA advisory committee for DMD cardiomyopathy effectiveness.
- regulator_advisory_bodyFDA Cellular, Tissue and Gene Therapies Advisory Committee
Voted 3-9 that available evidence does not support Deramiocel effectiveness for the specified indication; non-binding.
